针对具有MET外显子14改变的转移性非小细胞肺癌的新型疗法：卡马替尼聚焦

Tan Aaron C, Loh Tracy J, Kwang Xue Lin, Tan Gek San, Lim Kiat Hon, Tan Daniel S W

Division of Medical Oncology, National Cancer Centre Singapore, Singapore, 169610, Singapore.

Department of Pathology, Singapore General Hospital, Singapore, 169608, Singapore.

Lung Cancer (Auckl). 2021 Mar 18;12:11-20. doi: 10.2147/LCTT.S263610. eCollection 2021.

MET exon 14 (METex14) alterations are now an established therapeutically tractable target in non-small cell lung cancer (NSCLC). Recently reported trials of several MET tyrosine kinase inhibitors (TKI) in this patient population have demonstrated promising efficacy data in both the treatment naïve and pre-treated settings and have led to regulatory approvals. This review will focus on practical diagnostic considerations for METex14 alterations, the trial evidence for capmatinib in this molecular subset including dosing and toxicity management, and the future therapeutic landscape of METex14 altered NSCLC.

MET外显子14（METex14）改变现在是非小细胞肺癌（NSCLC）中一个已确立的可治疗靶点。最近报道的几项MET酪氨酸激酶抑制剂（TKI）在该患者群体中的试验，在初治和经治患者中均显示出有前景的疗效数据，并已获得监管批准。本综述将重点关注METex14改变的实际诊断考量、卡马替尼在这一分子亚组中的试验证据，包括给药方案和毒性管理，以及METex14改变的NSCLC的未来治疗前景。